Skip to main content

Table 2 Baseline descriptive statistics of the treatment groups composed of patients with global heart T2* value < 20 ms

From: Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

  P Deferiprone group (n = 9) Combined group (n = 26) Deferoxamine group (n = 21) P
Age (yrs) 0.358 29.7 ± 5.2 27.6 ± 5.7 32.8 ± 6.5 0.005
Male (%) 0.700 66.7% 53.8% 23.8% 0.072
Chel. starting age (yrs) 0.918 5.0 ± 3.5 5.3 ± 5.3 6.7 ± 6.0 0.504
Mean pre-transfusion Hb (g/dl) 0.180 9.9 ± 0.4 9.6 ± 0.5 9.8 ± 0.6 0.217
Mean serum ferritin (ng/l) 0.001 1475 ± 2753 2135 ± 966 1367 ± 988 <0.0001
Global Heart (ms) 0.112 12.8 ± 3.6 10.2 ± 4.3 14.4 ± 4.3 0.002
MRI CIC (mg/g dry weight) 0.096 2.20 ± 0.77 3.56 ± 2.65 1.99 ± 0.90 0.002
N seg. With T2* < 20 ms 0.502 14.8 ± 1.8 15.2 ± 1.7 13.0 ± 3.3 0.010
Mid septum T2* (ms) 0.194 13.3 ± 5.2 10.6 ± 5.4 14.6 ± 5.0 0.012
LV EF (%) 0.466 58.9 ± 5.9 61.1 ± 8.3 59.9 ± 6.8 0.583
LV EDVI (ml/m2) 0.749 90.2 ± 18.5 87.5 ± 22.2 89.9 ± 20.5 0.712
RV EF (%) 0.023 54.9 ± 5.7 60.2 ± 5.7 60.4 ± 6.0 0.927
RV EDVI (ml/m2) 0.737 89.3 ± 20.7 86.7 ± 19.7 86.1 ± 21.3 0.926
Liver T2* (ms) 0.011 7.5 ± 5.0 3.5 ± 3.5 8.2 ± 6.4 0.005
MRI LIC (mg/g dry weight) 0.018 8.4 ± 12.9 14.8 ± 11.8 6.8 ± 7.0 0.003
  1. All values are quoted as mean ± SD. The P-values concern the comparison between combined and deferiprone groups and between combined and deferoxamine groups.